Overview
NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
Last reviewed: 15 January 2025
Next review: We will review this decision if the company decides to make an evidence submission.